Leap Therapeutics sells IL-1ß antibody assets to AlmataBio for $500K cash plus up to $70M milestones

CYPHERPUNK TECHNOLOGIES INC.

Entered into Asset Purchase Agreement with AlmataBio for IL-1ß antibodies FL-101 and FL-103.
Received $500,000 cash at closing; potential milestone payments up to $70 million tied to regulatory and sales milestones.
Buyer assumed all liabilities related to the transferred assets.
80% of after-tax net proceeds from sale to be paid to former Flame Biosciences equityholders as additional merger consideration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.